PONTE
VEDRA, Fla., May 23, 2024
/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD),
a biopharmaceutical company developing tecarfarin, a late-stage
novel oral and reversible anticoagulant (blood thinner) designed to
prevent heart attacks, strokes and deaths due to blood clots in
patients with rare cardiovascular conditions, will participate in a
webcasted presentation and host one-on-one meetings with investors
at the Lytham Partners Spring 2024 Investor Conference, taking
place virtually on Thursday, May 30,
2024.
Company Webcast
The webcasted presentation will take
place at 12:30pm ET on Thursday, May 30,
2024. The webcast can be accessed by visiting the conference
home page at https://lythampartners.com/spring2024/ or directly at
https://wsw.com/webcast/lytham11/cvkd/2082696. The webcast will
also be available for replay following the event.
1×1 Meetings
Management will be participating in
virtual one-on-one meetings throughout the event. To arrange a
meeting with management, please contact Lytham Partners at
1×1@lythampartners.com or register for the event at
https://lythampartners.com/spring2024invreg/.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is developing tecarfarin for unmet needs in
anticoagulation therapy. Tecarfarin is a late-stage novel oral and
reversible anticoagulant (blood thinner) to prevent heart attacks,
strokes, and deaths due to blood clots in patients with rare
cardiovascular conditions who require chronic anticoagulation.
Tecarfarin has orphan drug and fast-track designations from the FDA
for the prevention of systemic thromboembolism (blood clots) of
cardiac origin in patients with end-stage kidney disease (ESKD) and
atrial fibrillation (AFib). Tecarfarin also has orphan drug
designation for the prevention of thrombosis and thromboembolism in
patients with ventricular assist devices (VADs). Cadrenal is also
pursuing additional regulatory strategies for unmet needs in
anticoagulation therapy for patients with thrombotic
antiphospholipid syndrome (APS). Tecarfarin is specifically
designed to leverage a different metabolism pathway than the oldest
and most commonly prescribed Vitamin K Antagonist (warfarin).
Tecarfarin has been evaluated in eleven (11) human clinical trials
and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3
clinical trials, tecarfarin has generally been well-tolerated in
both healthy adult subjects and patients with chronic kidney
disease. For more information, please visit:
www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-the-lytham-partners-spring-2024-investor-conference-on-may-30-2024-302153439.html
SOURCE Cadrenal Therapeutics, Inc.